Showing 1811-1820 of 2038 results for "".
- Nicox Granted Patent for NCX 470 in China, Extending Coverage to 2039https://modernod.com/news/nicox-granted-patent-for-ncx-470-in-china-extending-coverage-to-2039/2480655/Nicox SA announced that the Chinese National Intellectual Property Administration (CNIPA) has granted the company a formulation patent for NCX 470, its lead product candidate in development for patients with open-angle glaucoma or ocular hypertension, extending coverage in China to 2039. Wit
- Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operationshttps://modernod.com/news/outlook-therapeutics-expands-commercial-team-with-appointment-of-senior-vice-president-of-commercial-operations/2480623/Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
- The Vision Council Concludes Virtual Annual Business Meetinghttps://modernod.com/news/the-vision-council-concludes-virtual-annual-business-meeting/2480592/The Vision Council hosted its annual Business Meeting in a virtual format January 24. Presented under the banner of “It’s All Connected,” the meeting included a welcome address from Karen Roberts, The Vision Council’s Chair, followed by remarks from Ashley Mil
- Modular Super-Enhancer Controls Retinal Developmenthttps://modernod.com/news/modular-super-enhancer-controls-retinal-development/2480571/Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer. Enhancers are regions of DNA that do not
- Bausch + Lomb Files Registration Statement for Proposed Initial Public Offeringhttps://modernod.com/news/bausch-lomb-corporation-files-registration-statement-and-preliminary-prospectus-for-proposed-initial-public-offering/2480570/Bausch Health Companies announced that in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb, has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SE
- Nicox European Patent Seals Zerviate Major Market Coverage to 2030https://modernod.com/news/nicox-european-patent-seals-zerviate-major-market-coverage-to-2030/2480545/Nicox announced that patent EP2408453, covering the company’s product Zerviate (cetirizine ophthalmic solution) 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of Zerviate which is commercialized in the US by exclusive US licensee
- Haag-Streit to Focus on Surgical Microscopes in Ophthalmologyhttps://modernod.com/news/haag-streit-to-focus-on-surgical-microscopes-in-ophthalmology/2480524/Haag-Streit announced that it was focus its business moving forward on ophthalmology—discontinuting its surgical product portfolio in neurosurgery, spine surgery, ENT and plastic-reconstructive surgery. "For our customers, this focus on eye care will allow us to offer so
- Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseaseshttps://modernod.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/The Foundation Fighting Blindness announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation. The program will provide funding for six early translational research projects over 3 years for the dev
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas